Last reviewed · How we verify
HDS vs ProMECE/CytaBOM
HDS vs ProMECE/CytaBOM are competing chemotherapy regimens designed to treat aggressive lymphomas through different combinations of cytotoxic agents.
HDS vs ProMECE/CytaBOM are competing chemotherapy regimens designed to treat aggressive lymphomas through different combinations of cytotoxic agents. Used for Aggressive non-Hodgkin lymphoma, Hodgkin lymphoma (advanced stage).
At a glance
| Generic name | HDS vs ProMECE/CytaBOM |
|---|---|
| Sponsor | Gruppo Italiano Studio Linfomi |
| Drug class | Multi-agent chemotherapy regimen |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
HDS (high-dose sequential) and ProMECE/CytaBOM are multi-agent chemotherapy combinations used in lymphoma treatment. ProMECE/CytaBOM combines prednisone, methotrexate, etoposide, cyclophosphamide, doxorubicin, bleomycin, and other agents in a specific sequence. HDS represents an alternative high-dose approach. These are comparative regimens rather than a single drug entity.
Approved indications
- Aggressive non-Hodgkin lymphoma
- Hodgkin lymphoma (advanced stage)
Common side effects
- Myelosuppression
- Nausea and vomiting
- Alopecia
- Mucositis
- Infection
- Cardiotoxicity
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HDS vs ProMECE/CytaBOM CI brief — competitive landscape report
- HDS vs ProMECE/CytaBOM updates RSS · CI watch RSS
- Gruppo Italiano Studio Linfomi portfolio CI